ADC Therapeutics (ADCT) Amortization - Deferred Charges: 2019-2023
Historic Amortization - Deferred Charges for ADC Therapeutics (ADCT) over the last 5 years, with Sep 2023 value amounting to -$12.9 million.
- ADC Therapeutics' Amortization - Deferred Charges fell 13.97% to -$12.9 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$39.2 million, marking a year-over-year decrease of 33.50%. This contributed to the annual value of -$36,924 for FY2022, which is 101.33% down from last year.
- Latest data reveals that ADC Therapeutics reported Amortization - Deferred Charges of -$12.9 million as of Q3 2023, which was up 18.38% from -$15.9 million recorded in Q2 2023.
- ADC Therapeutics' Amortization - Deferred Charges' 5-year high stood at -$32 during Q3 2019, with a 5-year trough of -$15.9 million in Q2 2023.
- Its 3-year average for Amortization - Deferred Charges is -$7.0 million, with a median of -$8.8 million in 2022.
- Data for ADC Therapeutics' Amortization - Deferred Charges shows a maximum YoY crashed of 6,062,400.00% (in 2020) over the last 5 years.
- ADC Therapeutics' Amortization - Deferred Charges (Quarterly) stood at -$51 in 2019, then slumped by 6,062,400.00% to -$1.9 million in 2020, then plummeted by 119.85% to -$9,520 in 2021, then declined by 2.98% to -$9,804 in 2022, then declined by 13.97% to -$12.9 million in 2023.
- Its last three reported values are -$12.9 million in Q3 2023, -$15.9 million for Q2 2023, and -$10.4 million during Q1 2023.